Rate My Professor Nat Milton

Professor Milton's research centers on Alzheimer’s drug discovery and diagnostics, exploring amyloid peptides in Alzheimer’s disease, diabetes, Creutzfeldt-Jakob disease, and oxidative stress responses. Key discoveries include neuroprotective effects of endogenous cannabinoids like anandamide against amyloid-β neurotoxicity, KiSS-1 derivatives such as kissorphin as anti-opioid peptides binding amyloid proteins, and bioinformatics analyses of protein interactions like amyloid-β with catalase for therapeutic applications. Notable publications encompass 'SARS-CoV-2 amyloid, is COVID-19-exacerbated dementia an amyloid disorder in the making?' (Frontiers in Dementia, 2023), 'Kissorphin peptides for use in the treatment of Alzheimer’s disease, Creutzfeldt-Jakob disease or diabetes mellitus' (UK Patent GB2493313B, 2017), and the book chapter 'Polymorphism of Amyloid Fibrils and their Complexes with Catalase' (Bio-nanoimaging, 2014). He presented his inaugural lecture, 'Amyloid-β, the Poison in Your Human Machine,' at the University of Chichester.